查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1247465

2023-2030 年全球血液腫瘤檢測市場

Global Hemato Oncology Testing Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

全球血液腫瘤檢測市場預計將實現利潤豐厚的增長，到 2022 年將達到 2.8 億美元，到 2030 年將達到 6.2 億美元。 在預測期內（2023 年至 2030 年），該市場的複合年增長率為 4.8%。

血液腫瘤學結合了兩個醫學領域：研究血液的血液學和研究癌症的腫瘤學。 血液腫瘤學家接受過血癌和血液相關疾病的診斷、治療和預防方面的培訓。 血液腫瘤學領域涉及血液和相關癌症的治療。

市場動態

藥物診斷和服務的技術進步

市場的不斷進步和技術先進的新產品的推出正在推動全球血液腫瘤檢測市場的增長。 例如，2022 年 8 月，Thermo Fisher Scientific 宣布推出 CE-IVD (IVDD) 下一代測序和分析軟件，以擴大精準腫瘤生物標誌物檢測的範圍。 同樣，2022 年 6 月，Burning Rock Biotech Limited 獲得了 OverC 多癌評估血液測試的 CE 標誌。 OverC 多癌推定血液檢測是一種基於下一代測序儀 (NGS) 的定性體外診斷設備。 同樣，2021 年 11 月，聖地亞哥和遺傳聯盟啟動了 iHope Genetic Health 計劃，旨在為全球數萬名患有遺傳病的人提供全基因組測序訪問（WGS）。

個性化醫療意識的增強正在為市場創造有利可圖的增長機會。

個性化醫療是一種快速發展的醫療實踐，它使用個人的基因概況來做出預防、診斷和治療疾病的決策。 了解患者的遺傳概況後，醫生可以選擇最準確的藥物和治療方法，並使用適當的劑量和方案進行管理。 例如，2021 年 1 月，隨著個性化醫療的作用不斷擴大，FDA 承諾向醫生提供有關設計新療法的知識。 此外，歐洲癌症患者聯盟 (ECPC) 將在 11 月領導第一個個性化醫療宣傳月，ECPC 在為期一個月的名為“個性化醫療宣傳月”的宣傳活動中倡導癌症分子檢測。宣傳獲得癌症的重要性：破譯癌症密碼”。

內容

第 1 章研究方法和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章定義和概述

第 3 章執行摘要

  • 按產品/服務類型分類的摘要
  • 按技術分類的片段
  • 按癌症類型分類的摘要
  • 最終用戶的片段
  • 區域摘要

第 4 章動力學

  • 影響因子
    • 司機
      • 藥物診斷和服務方面的技術進步
      • 全球範圍內血癌的患病率正在上升
    • 約束因素
      • 不利和不確定的贖回情景
    • 機會
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • 在 COVID-19 情景之前
    • 當前的 COVID-19 情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 結論

第 7 章按產品/服務類型

  • 儀器
  • 試劑和耗材
  • 服務內容

第八章技術

  • PCR（聚合□鍊式反應）
  • IHC（免疫組織化學）
  • NGS（下一代測序）
  • 細胞遺傳學
  • 其他

第 9 章按癌症類型分類

  • 白血病
    • 急性髓性白血病
    • 急性淋巴細胞白血病
    • 其他
  • 淋巴瘤
  • 多發性骨髓瘤
  • 其他

第 10 章最終用戶

  • 臨床實驗室
  • 醫院
  • 學術和研究機構等
  • 其他

第11章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 俄羅斯
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第12章競爭格局

  • 競爭場景
  • 市場分析/份額分析
  • 併購分析

第13章公司簡介

  • F. Hoffman-La Roche Ltd.
    • 公司簡介
    • 產品組合和說明
    • 財務摘要
    • 主要發展
  • Abbott Laboratories
  • Qiagen N.V.
  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • Bio-Rad Laboratories, Inc.
  • ICON PLC
  • Archerdx, Inc.
  • Invivoscribe, Inc.
  • Adaptive Biotechnologies

第14章 附錄

簡介目錄
Product Code: CD1347

Market Overview

The global hemato oncology Testing market reached US$ 280 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 620 million by 2030. The market is growing at a CAGR of 4.8% during the forecast period (2023-2030).

Hematologic oncology integrates two fields of medicine: hematology, the study of the blood, and oncology, the study of cancer. Hematologic oncologists are trained in diagnosing, treating, and preventing blood cancers and blood-related disorders. The field of haemato-oncology deals with the treatment of blood and related cancers.

Market Dynamics

Technological advancements in drug diagnosis and services

The growing advancements and new technologically advanced product introductions into the market are boosting the global hemato oncology testing market growth. For instance, in August 2022, Thermo Fisher Scientific introduced CE-IVD (IVDD) next-generation sequencing test and analysis software to extend access to precision oncology biomarker testing. Likewise, in June 2022, Burning Rock Biotech Limited was granted a CE marking for its OverC multi-cancer estimation blood test. OverC Multi-Cancer Detection Blood Test is a qualitative next-generation sequencing (NGS)-based in vitro diagnostic device. Similarly, in November 2021, SAN DIEGO and Genetic Alliance created the iHope Genetic Health program targeted at delivering whole-genome sequencing access (WGS) to tens of thousands of individuals all over the globe affected by genetic disease.

Growing awareness regarding personalized medicines is presenting the market with lucrative growth opportunities.

Personalized medicine is a blossoming practice of medicine that employs an individual's genetic profile to direct decisions formed for the prevention, diagnosis, and treatment of the disorder. Knowledge of a patient's genetic profile can aid physicians to choose the most accurate medication or therapy and administer it utilizing the appropriate dose or regimen. The growing awareness and efforts to implement personalized medicine are providing the market with very lucrative growth opportunities For instance, in January 2021, the FDA declared its involvement in providing physicians with knowledge on the designing of novel therapies as the role of personalized medicine keeps on expanding. Furthermore, the European Cancer Patient Coalition (ECPC) lead the first Personalized Medicine Awareness Month throughout November, the ECPC promoted the significance of access to cancer molecular testing during a month-long advocacy campaign called, Personalized Medicine Awareness Month: Cracking the Cancer Code.

Segment Analysis

The global hemato oncology testing market is segmented based on Product & Services, Cancer Type, Technology, and region.

Owing to growing new technological advancements, product launches, and recent development

The increasing market developments such as collaborations, and product launches among others are boosting the services segment growth during the forecast period. For instance, in August 2020 Thermo Fisher Scientific introduced hematology-oncology assays for the Ion Torrent Genexus System. Also, in May 2022, the Qatar Foundation (QF) division of the Qatar Genome Program (QGP), and Thermo Fisher Scientific partnered for the advancement of genomic research and clinical applications of predictive genomics in Qatar as a step in the direction of expanding the benefits of precision medicine all over the Arab populations worldwide. Similarly, in August 2022, Mount Sinai Health System and the Icahn School of Medicine introduced a new human genome sequencing research project known as the Mount Sinai Million Health Discoveries Program with the Regeneron Genetics Center (RGC). Thus, the mentioned data indicates that the services segment will dominate the global hemato-oncology testing market throughout the forecast period.

Geographical Penetration

The strong presence of major players and increased awareness about the use of eco-friendly products

North America dominates the global hemato oncology testing market during the forecast period, owing to the growing cases of leukemia, better reimbursement policies, and the presence of key market players holding the majority of the market in this region. For instance, according to the Canada Cancer Society report that there were over 6,700 Canadians diagnosed with leukemia, of which around 4,000 were men and about 2,700 were women in 2021. Also, the American Cancer Society documented that approximately 60,650 new cases of leukemia and 20,050 new cases of acute myeloid leukemia (AML) were diagnosed in the United States in 2022. Also, acute myeloid leukemia (AML) made up only about 1% of all cancers. Furthermore, Abbott Laboratories, Thermofisher Scientific, and Illumina are among the key market players holding the majority of market share based in the North American region ensuring the dominance of the region over the global market.

Competitive Landscape

The major global players include F. Hoffman-La Roche Ltd., Abbott Laboratories, Qiagen N.V., Thermo Fisher Scientific, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., ICON PLC, Archerdx, Inc., Invivoscribe, Inc., and Adaptive Biotechnologies.

COVID-19 Impact Analysis

By Type of Product & Service

  • Instruments
  • Reagents & Consumables
  • Services

By Technology

  • PCR (Polymerase Chain Reaction)
  • IHC (immunohistochemical)
  • NGS (Next-Generation Sequencing)
  • Cytogenetics
  • Others

By Cancer Type

  • Leukemia
    • Acute Myeloid Leukemia
    • Acute Lymphocytic Leukemia
    • Others
  • Lymphoma
  • Multiple myelomas
  • Others

By End-user

  • Clinical Laboratories
  • Hospitals
  • Academic & Research Institutes
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Russia
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In 2022, the US FDA granted approval to F. Hoffmann-La Roche Ltd. (Switzerland) for its cobras EZH2 mutation test as a companion diagnostic for patients with follicular lymphoma.
  • In 2020, F. Hoffmann-La Roche Ltd. (Switzerland) and Illumina Inc. (US) formed a 15-year non-exclusive collaboration with Illumina to extend the adoption of NGS-based testing in oncology.
  • In 2021, QIAGEN N.V. (Germany) and Denovo Biopharma LLC (US) formed a partnership to design a blood-based companion diagnostic (CDx) test for the treatment of diffuse large B-cell lymphoma (DLBCL), one of the most typical lymphoid cancers.

Why Purchase the Report?

  • To visualize the global Hemato Oncology Testing- market segmentation based on product, application and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of Hemato Oncology Testing market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global Hemato Oncology Testing market report would provide approximately 69 tables, 71 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type of Products & Services
  • 3.2. Snippet by Technology
  • 3.3. Snippet by Type of cancer
  • 3.4. Snippet by End-user
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Technological Advancements In Drug Diagnosis And Services
      • 4.1.1.2. Increasing Prevalence of Hematologic Cancer Globally
      • 4.1.1.3. XX
    • 4.1.2. Restraints
      • 4.1.2.1. Unfavorable And Uncertain Reimbursement Scenario
      • 4.1.2.2. XX
    • 4.1.3. Opportunity
      • 4.1.3.1. XX
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type of Product & Service

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type of Product & Service
    • 7.1.2. Market Attractiveness Index, By Type of Product & Service
  • 7.2. Instruments
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Reagents & Consumables
  • 7.4. Services

8. By Technology

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.1.2. Market Attractiveness Index, By Technology
  • 8.2. PCR (Polymerase Chain Reaction) *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. IHC (immunohistochemical)
  • 8.4. NGS (Next-Generation Sequencing)
  • 8.5. Cytogenetics
  • 8.6. Others

9. By Cancer Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 9.1.2. Market Attractiveness Index, By Cancer Type
  • 9.2. Leukemia*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 9.2.3. Acute Myeloid Leukemia
    • 9.2.4. Acute Lymphocytic Leukemia
    • 9.2.5. Others
  • 9.3. Lymphoma
  • 9.4. Multiple myelomas
  • 9.5. Others

10. By End-user

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 10.1.2. Market Attractiveness Index, By End-user
  • 10.2. Clinical Laboratories*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Hospitals
  • 10.4. Academic & Research Institutes
  • 10.5. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type of Product & Service
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Caner Type
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Caner Type
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.6.1. Germany
      • 11.3.6.2. UK
      • 11.3.6.3. France
      • 11.3.6.4. Italy
      • 11.3.6.5. Russia
      • 11.3.6.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Caner Type
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.6.1. Brazil
      • 11.4.6.2. Argentina
      • 11.4.6.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Caner Type
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.6.1. China
      • 11.5.6.2. India
      • 11.5.6.3. Japan
      • 11.5.6.4. Australia
      • 11.5.6.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Caner Type
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. F. Hoffman-La Roche Ltd.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Abbott Laboratories
  • 13.3. Qiagen N.V.
  • 13.4. Thermo Fisher Scientific, Inc.
  • 13.5. Illumina, Inc.
  • 13.6. Bio-Rad Laboratories, Inc.
  • 13.7. ICON PLC
  • 13.8. Archerdx, Inc.
  • 13.9. Invivoscribe, Inc.
  • 13.10. Adaptive Biotechnologies

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us